CJC-1295 is sold in two distinct forms that share the same core GHRH-analog sequence but behave very differently in a research timeline. The difference comes down to a single addition — a Drug Affinity Complex, or DAC — that transforms the compound's pharmacokinetic profile without altering the receptor it targets. This article breaks down the mechanism behind that difference, what each form is best suited to isolate in a study design, and how they compare to the rest of the GHRH-axis peptide family.
Same Receptor, Same Sequence, One Structural Difference
Both forms of CJC-1295 are built on the same modified GHRH(1-29) backbone, engineered to resist enzymatic degradation and bind the GHRH receptor (GHRH-R) with high affinity. CJC-1295 without DAC — sometimes called Mod GRF (1-29) in the literature — is this core sequence on its own. CJC-1295 with DAC is the identical sequence with a Drug Affinity Complex appended to the C-terminus. That addition doesn't change which receptor the peptide binds or how it activates GHRH-R once bound — it changes how long the peptide circulates before being cleared, which is the entire point of the modification.
How DAC Extends Half-Life: The Albumin-Binding Mechanism
The Drug Affinity Complex works by giving the peptide a covalent binding site for serum albumin, the most abundant protein in circulating blood. Once bound to albumin, the peptide is effectively shielded from the renal filtration and enzymatic degradation processes that would otherwise clear it quickly, and it's released gradually as the albumin-peptide complex circulates. This is a fundamentally different half-life-extension strategy than the one used in tesamorelin, which relies on a DPP-4-resistant N-terminal modification rather than albumin binding — we cover that mechanism in more depth in our tesamorelin research guide. The practical result for CJC-1295 with DAC is a functional half-life measured in days rather than minutes, driven entirely by this albumin-shielding effect rather than any change in receptor-binding kinetics.
The Numbers: Roughly 30 Minutes vs. Roughly a Week
CJC-1295 without DAC has a functional half-life in the range of 30 minutes, which places it much closer to native GHRH's rapid clearance profile than to a long-acting analog. That short window is a feature for certain research designs, not a limitation: it produces a signal that more closely mimics the pulsatile pattern of endogenous GHRH release, making it a useful tool for studying pulse-dependent downstream effects. CJC-1295 with DAC, by contrast, extends that half-life to roughly a week through the albumin-binding mechanism described above — producing sustained GHRH-receptor engagement rather than a pulsatile signal. Researchers choosing between the two forms are really choosing between studying pulsatile versus sustained receptor activation, which is a meaningfully different experimental question even though both forms converge on the same receptor.
Pulsatile vs. Sustained Signaling: Why the Choice Matters for Study Design
This distinction matters because GHRH-receptor signaling doesn't behave identically under pulsatile versus continuous activation. Sustained receptor engagement can engage negative feedback mechanisms — including somatostatin-mediated inhibition and receptor desensitization — differently than intermittent pulses do. A study built around CJC-1295 without DAC and designed with frequent sampling intervals can capture pulse-dependent dynamics that a CJC-1295 with DAC protocol, with its sustained profile, isn’t built to show — and vice versa for studies examining prolonged receptor occupancy. Neither form is more “correct” than the other; they're suited to different research questions within the same GHRH-receptor mechanism, which is part of why both forms are commonly stocked side by side in labs working across this pathway.
CJC-1295 vs. the Rest of the GHRH-Axis Family
- CJC-1295 without DAC — short half-life (~30 minutes), pulsatile-signal research, closest analog to native GHRH's clearance behavior.
- CJC-1295 with DAC — extended half-life (~days) via albumin binding, sustained GHRH-receptor engagement.
- Tesamorelin — intermediate half-life extension via DPP-4 resistance rather than albumin binding, preserves pulsatile GH release in preclinical models.
- Sermorelin — shortest GHRH fragment of the group, minimal half-life extension, useful for the most transient signaling designs.
Researchers building a comparative panel across half-life variants often source several of these together — we go into more depth on how the full secretagogue family compares in our Sermorelin vs. Ipamorelin vs. CJC-1295 comparison. Also worth combining into a broader panel is Ipamorelin, which engages the ghrelin receptor rather than GHRH-R, giving researchers a way to separate GHRH-specific effects from broader secretagogue-pathway effects.
What to Control For When Comparing DAC and Non-DAC Forms
Because the two forms differ primarily in pharmacokinetics rather than receptor pharmacology, comparative study designs should hold sampling protocol constant as a controlled variable rather than an afterthought — a short sampling window that works for the non-DAC form will systematically undersample the DAC form's sustained profile, and vice versa. Peptide stability during the study period also matters more for the DAC form given its longer intended circulation time; degraded albumin-binding capacity would undermine the entire premise of the extended-half-life design. Our guide to reproducible peptide study design covers these considerations in more general terms, and they apply directly when comparing DAC and non-DAC analogs head to head.
Sourcing Both Forms for Comparative Research
Because the DAC modification is structurally more complex than the base sequence, purity verification is arguably more important for the DAC form — an incompletely conjugated batch could contain a mixture of DAC-bound and unbound peptide with meaningfully different pharmacokinetics. A batch-specific Certificate of Analysis confirming both purity and molecular identity is the standard to hold any supplier to; our COA standards guide covers what to look for. Both CJC-1295 without DAC and CJC-1295 with DAC are available in our research-grade catalog, manufactured to ≥99% purity with independent third-party testing and a batch-specific COA for every lot — making a controlled, sourcing-consistent comparison between the two straightforward to design.
CJC-1295 DAC vs. No-DAC FAQ
Does DAC change what receptor CJC-1295 binds?
No. Both forms bind GHRH-R with the same core sequence; DAC only affects pharmacokinetics by adding an albumin-binding domain, not receptor selectivity.
Which form better mimics native GHRH signaling?
CJC-1295 without DAC, due to its short half-life, more closely approximates native GHRH's pulsatile clearance pattern than the DAC-extended form does.
Why would a study use the DAC form instead?
Studies examining sustained versus intermittent GHRH-receptor occupancy, or designs where infrequent sampling is a practical constraint, are better matched to the DAC form's extended half-life.
How does CJC-1295 with DAC compare to tesamorelin's half-life extension?
Both extend half-life relative to native GHRH, but through different mechanisms — DAC uses albumin binding, while tesamorelin uses a DPP-4-resistant N-terminal modification. DAC produces the longer extension of the two.
Cited Research Literature
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. PubMed PMID 16352683
- Ionescu M, Frohman LA. Pulsatile growth hormone secretion during continuous stimulation with CJC-1295. PubMed PMID 17018654
Choosing the Right CJC-1295 Form for Your Research
The choice between CJC-1295 without DAC and CJC-1295 with DAC isn't about which is the “better” compound — it's about which pharmacokinetic profile matches the research question. Pulsatile-signal studies and sustained-engagement studies are different experiments, and CJC-1295's two forms give researchers a matched pair, built on identical receptor pharmacology, to address either one.
All products are sold strictly for laboratory and in vitro research use only, and are not intended for human or veterinary use, diagnostic procedures, or any application outside a qualified research setting.